×

NanoString Technologies to Release Third Quarter 2014 Financial Results and Host Conference Call on Tuesday, November 4, 2014

SEATTLE, Oct. 9, 2014 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (Nasdaq:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that the Company will release third quarter 2014 financial results after the close of trading on Tuesday, November 4, 2014. Company management will host a conference call beginning at 4:30pm ET to discuss those results and to provide a business update.

Individuals interested in listening to the conference call may do so by dialing (888) 793-9492 for domestic callers, or (734) 385-2643 for international callers, or from the webcast link in the investor relations section of the Company's website at: www.nanostring.com.

A replay of the call will be available beginning November 4, 2014 at 7:30pm ET through midnight on November 5, 2014. To access the replay, dial (855) 859-2056 or (404) 537-3406 and reference Conference ID: 17072966. The webcast will also be available on the Company's website for one quarter following the completion of the call.

About NanoString Technologies, Inc.

NanoString Technologies provides life science tools for translational research and molecular diagnostic products. The company's nCounter® Analysis System has been employed in life sciences research since it was first introduced in 2008 and has been cited in more than 500 peer-reviewed publications. The nCounter Analysis System offers a cost-effective way to easily profile the expression of hundreds of genes, miRNAs, or copy number variations, simultaneously with high sensitivity and precision, facilitating a wide variety of basic research and translational medicine applications, including biomarker discovery and validation. The company's technology has now been applied to diagnostic use. The Prosigna® Breast Cancer Prognostic Gene Signature Assay together with the nCounter Dx Analysis System is FDA 510(k) cleared for use as a prognostic indicator for distant recurrence of breast cancer.

For more information, please visit www.nanostring.com.

CONTACT: Investor Contact: Leigh Salvo of Westwicke Partners For NanoString Technologies leigh.salvo@westwicke.com 415-513-1281 Media Contact: Nicole Litchfield of Bioscribe Inc. For NanoString Technologies nicole@bioscribe.com 415-793-6468

Source:NanoString Technologies, Inc.